Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-debate-20260411-065018-92a34465_20260416-134725",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Mechanistically Novel Hypotheses: Synaptic Vesicle Protein Modifications in Synaptic Dysfunction\n\n---\n\n## Hypothesis 1: SV2A Glycosylation Defects Disrupt Anticipatory Vesicle Recruitment and Promote Hippocampal Hyperexcitability\n\n**Mechanism:**\nSV2A, the binding target of the antiepileptic drug levetiracetam, undergoes N-linked glycosylation at Asn458 and Asn579 within its major facilitator superfamily domains. In AD brains, altered glycosyltransferase expression in presynaptic terminals leads to hypoglycosylated SV2A, reducing its interaction with the synaptotagmin-1/SNARE complex during action potential trains. This impairs \"anticipatory\" vesicle recruitment at high-frequency firing, producing a compensatory increase in release probability followed by rapid depletion—a hallmark of hippocampal network hyperexcitability observed in early AD.\n\n**Key Evidence:**\n- SV2A glycosylation is essential for its functional integration into synaptic vesicles and modulation of evoked release (PMID: 15634647)\n- CSF levels of SV2A are elevated in AD, suggesting synaptic stress and compensatory trafficking (PMID: 29953872)\n- Levetiracetam efficacy in AD models requires intact SV2A glycosylation for binding (PMID: 23100316)\n\n**Testable Prediction:**\nPerform LC-MS/MS glycomics on isolated synaptic vesicles from 3xTg-AD mice at 3 vs. 12 months vs. age-matched controls, quantifying site-specific glycan occupancy at Asn458/579. If hypoglycosylation occurs with age, predicted: progressive loss of SV2A-Syt1 interaction by co-immunoprecipitation, correlating with increased spontaneous release frequency and reduced paired-pulse facilitation at 30 Hz stimulation ex vivo. Falsification: equal glycosylation across all ages/genotypes by lectin blot.\n\n**Target Gene/Protein:** SV2A (SV2A)\n\n---\n\n## Hypothesis 2: CDK5-Mediated Synapsin-1 Phosphorylation at Ser549/Ser567 Displaces Vesicles from Actin Cytoskeleton and Accelerates Tau-Pathology-Induced Synaptic Breakdown\n\n**Mechanism:**\nSynapsin-1 tethers synaptic vesicles to actin filaments via its C-terminal domain, a capacity blocked by CDK5-dependent phosphorylation at Ser549/Ser567. In AD, increased p25/p35 ratio hyperactivates CDK5, producing pathological hyperphosphorylation of synapsin-1. This severs the vesicle-actin linkage, dispersing the reserve pool and rendering vesicles accessible to pathogenic tau seeding at the presynaptic terminal. Tau oligomers at the bouton then recruit synapsin-1 into insoluble aggregates, creating a feedforward loop that collapses both reserve pool and active zone architecture.\n\n**Key Evidence:**\n- CDK5 phosphorylates synapsin-1 at conserved C-terminal sites, regulating vesicle dynamics (PMID: 15140750)\n- Tau oligomers bind presynaptic terminals and impair neurotransmitter release prior to postsynaptic deficits (PMID: 26849158)\n- Synapsin-1 is found in Triton-insoluble fractions in AD brain, co-aggregating with pathological proteins (PMID: 29246286)\n\n**Testable Prediction:**\nUse CRISPR-Cas9 to generate knock-in mice with Ser549/567Ala mutations (phosphorylation-dead synapsin-1) crossed into rTg4510 tauopathy mice. Hypothesis predicts: preservation of synaptic vesicle clusters at hippocampal CA3-CA1 synapses, measured by electron microscopy, and improved excitatory transmission at 6 months compared to tauopathy controls. Falsification: equivalent synaptic vesicle dispersal and tau pathology regardless of synapsin-1 phosphorylation status.\n\n**Target Gene/Protein:** Synapsin-1 (SYN1)\n\n---\n\n## Hypothesis 3: VAMP",
  "tokens_used": "882"
}